1383 related articles for article (PubMed ID: 31714636)
21. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
22. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Zhao SS; Yiu ZZN; Barton A; Bowes J
JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
[TBL] [Abstract][Full Text] [Related]
23. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
[TBL] [Abstract][Full Text] [Related]
24. Association between Lipid-Lowering Drugs and Traumatic Subdural Hemorrhage: A Mendelian Randomization Study.
Chen K; Li H; Chen Y; Huang H; Wei L
J Integr Neurosci; 2024 Apr; 23(4):76. PubMed ID: 38682216
[TBL] [Abstract][Full Text] [Related]
25. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
Rosoff DB; Bell AS; Jung J; Wagner J; Mavromatis LA; Lohoff FW
J Am Coll Cardiol; 2022 Aug; 80(7):653-662. PubMed ID: 35953131
[TBL] [Abstract][Full Text] [Related]
26. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
[TBL] [Abstract][Full Text] [Related]
27. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Ference BA; Robinson JG; Brook RD; Catapano AL; Chapman MJ; Neff DR; Voros S; Giugliano RP; Davey Smith G; Fazio S; Sabatine MS
N Engl J Med; 2016 Dec; 375(22):2144-2153. PubMed ID: 27959767
[TBL] [Abstract][Full Text] [Related]
28. Lipids, Apolipoproteins, Statins, and Intracerebral Hemorrhage: A Mendelian Randomization Study.
Yu Z; Zhang L; Zhang G; Xia K; Yang Q; Huang T; Fan D
Ann Neurol; 2022 Sep; 92(3):390-399. PubMed ID: 35655417
[TBL] [Abstract][Full Text] [Related]
29. Association of lipid lowering drugs and the risk of systemic lupus erythematosus: a drug target Mendelian randomization.
Wu T; Ye L; Wang S; Huang J; Zhang J
Front Pharmacol; 2023; 14():1258018. PubMed ID: 37964871
[No Abstract] [Full Text] [Related]
30. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
31. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
32. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations.
Ardissino M; Slob EAW; Reddy RK; Morley AP; Schuermans A; Hill P; Williamson C; Honigberg MC; de Marvao A; Ng FS
Eur J Prev Cardiol; 2024 Jun; 31(8):955-965. PubMed ID: 38294056
[TBL] [Abstract][Full Text] [Related]
33. Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.
Pham K; Mulugeta A; Lumsden A; Hyppӧnen E
Br J Clin Pharmacol; 2023 Oct; 89(10):2992-3004. PubMed ID: 37208559
[TBL] [Abstract][Full Text] [Related]
34. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Schmidt AF; Swerdlow DI; Holmes MV; Patel RS; Fairhurst-Hunter Z; Lyall DM; Hartwig FP; Horta BL; Hyppönen E; Power C; Moldovan M; van Iperen E; Hovingh GK; Demuth I; Norman K; Steinhagen-Thiessen E; Demuth J; Bertram L; Liu T; Coassin S; Willeit J; Kiechl S; Willeit K; Mason D; Wright J; Morris R; Wanamethee G; Whincup P; Ben-Shlomo Y; McLachlan S; Price JF; Kivimaki M; Welch C; Sanchez-Galvez A; Marques-Vidal P; Nicolaides A; Panayiotou AG; Onland-Moret NC; van der Schouw YT; Matullo G; Fiorito G; Guarrera S; Sacerdote C; Wareham NJ; Langenberg C; Scott R; Luan J; Bobak M; Malyutina S; Pająk A; Kubinova R; Tamosiunas A; Pikhart H; Husemoen LL; Grarup N; Pedersen O; Hansen T; Linneberg A; Simonsen KS; Cooper J; Humphries SE; Brilliant M; Kitchner T; Hakonarson H; Carrell DS; McCarty CA; Kirchner HL; Larson EB; Crosslin DR; de Andrade M; Roden DM; Denny JC; Carty C; Hancock S; Attia J; Holliday E; O'Donnell M; Yusuf S; Chong M; Pare G; van der Harst P; Said MA; Eppinga RN; Verweij N; Snieder H; ; Christen T; Mook-Kanamori DO; Gustafsson S; Lind L; Ingelsson E; Pazoki R; Franco O; Hofman A; Uitterlinden A; Dehghan A; Teumer A; Baumeister S; Dörr M; Lerch MM; Völker U; Völzke H; Ward J; Pell JP; Smith DJ; Meade T; Maitland-van der Zee AH; Baranova EV; Young R; Ford I; Campbell A; Padmanabhan S; Bots ML; Grobbee DE; Froguel P; Thuillier D; Balkau B; Bonnefond A; Cariou B; Smart M; Bao Y; Kumari M; Mahajan A; Ridker PM; Chasman DI; Reiner AP; Lange LA; Ritchie MD; Asselbergs FW; Casas JP; Keating BJ; Preiss D; Hingorani AD; ; Sattar N
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):97-105. PubMed ID: 27908689
[TBL] [Abstract][Full Text] [Related]
35. Low-density lipoprotein cholesterol and lifespan: A Mendelian randomization study.
Daghlas I; Gill D
Br J Clin Pharmacol; 2021 Oct; 87(10):3916-3924. PubMed ID: 33704808
[TBL] [Abstract][Full Text] [Related]
36. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
37. Associations of lipids and lipid-modifying drug target genes with atrial fibrillation risk based on genomic data.
Tao Y; Wang Y; Yin Y; Zhang K; Gong Y; Ying H; Jiang R
Lipids Health Dis; 2024 Jun; 23(1):175. PubMed ID: 38851763
[TBL] [Abstract][Full Text] [Related]
38. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
39. Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study.
Li S; Schooling CM
Sci Rep; 2022 Mar; 12(1):3478. PubMed ID: 35241713
[TBL] [Abstract][Full Text] [Related]
40. Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.
Cupido AJ; Reeskamp LF; Hingorani AD; Finan C; Asselbergs FW; Hovingh GK; Schmidt AF
JAMA Cardiol; 2022 Sep; 7(9):955-964. PubMed ID: 35921096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
